Tranexamic Acid in the Prevention of Postpartum Hemorrhage in Elective Caesarean Section
Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
In obstetrics, postpartum haemorrhage (PPH) continues to be a major contributor to maternal
morbidity and mortality worldwide. Uterine atony is the most common cause of PPH, and the
prophylactic use of uterotonics, specifically oxytocin, is the standard of care for PPH
prophylaxis. It is believed that tranexamic acid (TXA) can enhance the hemostatic process
further by inhibiting the fibrinolytic system.
TXA is an antifibrinolytic that has been studied in many different patient population for its
use in reducing blood loss ranging from gynaecological and non gynaecological surgeries, to
trauma patients. It has been found to reduce mortality in treatment of patients with PPH, and
recent evidence have found promising results in its use for prophylaxis of PPH.